Avinger Q3 2023 Earnings Report

Avinger EPS Results

• Actual EPS: -$2.92
• Consensus EPS: -$2.85
• Beat/Miss: Missed by -$0.07
• One Year Ago EPS: N/A

Avinger Revenue Results

• Actual Revenue: $1.82 million
• Expected Revenue: $2.40 million
• Beat/Miss: Missed by -$580.00 thousand
• YoY Revenue Growth: N/A

Avinger Announcement Details

• Quarter: Q3 2023
• Date: 10/26/2023
• Time: N/A

Avinger (NASDAQ:AVGR), a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.